U.S. Markets for Minimally Invasive Benign Prostatic Hyperplasia and Prostatitis Therapies
U.S. Markets for Minimally Invasive Benign Prostatic Hyperplasia and Prostatitis Therapies
$4,750.00
This analysis includes a discussion of products, current/forecast markets, competitors, and opportunites in the benign uterine condition therapy systems market, including global endometrial ablation systems, MR-guided focused ultrasound systems, uterine artery embolization systems, and hysteroscopes/fibroid removal systems.
Publisher: Meddevicetracker
- Description
- Contents
- Samples
This analysis includes a discussion of products, current/forecast markets, competitors, and opportunites in the benign uterine condition therapy systems market, including global endometrial ablation systems, MR-guided focused ultrasound systems, uterine artery embolization systems, and hysteroscopes/fibroid removal systems. The combined global market for these systems totaled nearly $1.3bn in 2015, and is expected to grow at a CAGR of 4.7% through 2020.
EXECUTIVE SUMMARY…………………………………………………………………………. ES-1
i.Methodology……………………………………………………………………….. ES-2
1.CLINICAL OVERVIEW…………………………………………………………………….. 1-1
1.1 Benign Prostatic Hyperplasia …………………………………………………… 1-1
1.1.1 Symptoms ………………………………………………………………. 1-2
1.1.2 Diagnosis………………………………………………………………… 1-4
1.1.3 Treatment ……………………………………………………………….. 1-4
1.2 Prostatitis………………………………………………………………………………. 1-8
1.2.1 Symptoms ………………………………………………………………. 1-9
1.2.2 Diagnosis………………………………………………………………. 1-11
1.2.3 Treatments ……………………………………………………………. 1-11
Exhibit 1-1: Overview of the Lower Urinary Tract …………………………………………. 1-3
Exhibit 1-2: Summary of Symptoms for Types of Prostatitis…………………………. 1-10
2.MINIMALLY INVASIVE PRODUCTS FOR BENIGN PROSTATICHYPERPLASIA……………………………………………………………………………….. 2-1
2.1 Established Therapeutic Approaches………………………………………… 2-1
2.1.1 Watchful Waiting ……………………………………………………… 2-2
2.1.2 Drug Therapy ………………………………………………………….. 2-2
2.1.2.1 Clinical Development………………………………….. 2-3
2.1.2.2 Market Forecast ………………………………………… 2-5
2.1.3 Surgical Treatment …………………………………………………… 2-7
2.1.3.1 Transurethral Resection of the Prostate………… 2-9
2.1.3.2 Transurethral Incision of the Prostate………….. 2-10
2.1.3.3 Stents …………………………………………………….. 2-10
2.1.3.4 Market Forecast ………………………………………. 2-10
2.1.4 Minimally Invasive Therapy ……………………………………… 2-14
2.1.4.1 Transurethral Microwave Thermotherapy…….. 2-14
2.1.4.2 Transurethral Needle Ablation……………………. 2-15
2.1.4.3 Laser-Based Therapy……………………………….. 2-16
2.1.4.4 Other Energy-Based Therapies………………….. 2-18
2.1.4.5 Prostate Artery Embolization……………………… 2-19
2.1.4.6 Prostate Implant ………………………………………. 2-20
2.1.4.7 Clinical Development………………………………… 2-20
2.1.4.8 Market Forecast ………………………………………. 2-22
2.1.4.9 Market Drivers and Limiters……………………….. 2-28
2.1.4.10 Competitive Analysis ………………………………… 2-29
Exhibit 2-1: Ongoing Clinical Trials for Pharmaceutical Therapies for the Treatment of Symptomatic BPH……………………………………………….. 2-6
Exhibit 2-2: 2015, Average Cost of Select Pharmaceuticals for Treatment of Benign Prostatic Hyperplasia Symptoms……………………………………. 2-8
Exhibit 2-3: Transurethral Resection of the Prostate, Procedure Volumes Forecast, 2014-2019 ……………………………………………….. 2-12
Exhibit 2-4: Transurethral Resection of the Prostate, Market Forecast, 2014-2019 …………………………………………………………….. 2-13
Exhibit 2-5: Minimally Invasive Treatments for Benign Prostatic Hyperplasia, Procedure Volumes Forecast, 2014-2019 ………………………………… 2-25
Exhibit 2-6: Minimally Invasive Treatments for Benign Prostatic Hyperplasia, Market Forecast, 2014-2019 ………………………………………………….. 2-27
Exhibit 2-7: 2014, Minimally Invasive Microwave/RF Thermotherapy Systems Market, Share by Supplier ……………………………………………………… 2-31
Exhibit 2-8: 2014, Minimally Invasive Laser-based Therapy Systems Market, Share by Supplier ……………………………………………………… 2-33
3.MINIMALLY INVASIVE PRODUCTS FOR PROSTATITIS ……………………. 3-1
3.1 Established Therapeutic Approaches………………………………………… 3-1
3.1.1 Drug Therapy ………………………………………………………….. 3-2
3.1.1.1 Anti-infectives……………………………………………. 3-4
3.1.1.2 Anti-Inflammatory and Analgesic Agents……….. 3-5
3.1.1.3 Narcotic Drugs…………………………………………… 3-5
3.1.1.4 Alpha-Adrenergic Blockers………………………….. 3-5
3.1.1.5 Clinical Development………………………………….. 3-7
3.1.1.6 Market Analysis …………………………………………. 3-8
3.1.2 Conservative Non-Pharmacologic Therapy………………….. 3-9
3.1.3 Surgical Treatment …………………………………………………. 3-10
3.1.4 Minimally Invasive Thermotherapy ……………………………. 3-10
3.1.4.1 Microwave Thermotherapy………………………… 3-11
3.1.4.2 Water-Induced Thermotherapy…………………… 3-12
3.2 Market Forecast …………………………………………………………………… 3-14
Exhibit 3-1: Treatment Algorithm for Patients with CBP and CPPS…………………. 3-3 Exhibit 3-2: Select Anti-infective Agents for the Treatment of Bacterial Prostatitis…………………………………………………………………. 3-6
Exhibit 3-3: Prostatitis Treatment, Advantages and Disadvantages of Minimally Invasive Thermotherapy ………………………………………….. 3-13
Exhibit 3-4: Minimally Invasive Prostatitis Treatments, Procedure Volumes Forecast, 2014-2019 …………………………………………………………….. 3-16
Exhibit 3-5: Minimally Invasive Prostatitis Treatments, Market Forecast, 2014-2019 ………………………………………………….. 3-17
APPENDIX: COMPANY LISTING……………………………………………………………… A-1
BIBLIOGRAPHY ……………………………………………………………………………………… B-1
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Global Spinal Implants Market 
Sign up to the